Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy
Conclusions
In premenopausal women with BC, 24 months of intravenous ZOL treatment significantly increased the LS BMD as well as the TBS.
Source: Osteoporosis International - Category: Orthopaedics Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Orthopaedics | Osteoporosis | Reclast | Study | Women | Zometa